Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Acceleron Pharma (XLRN) Stock Price

Media stories about Acceleron Pharma (NASDAQ:XLRN) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Acceleron Pharma earned a daily sentiment score of 0.11 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 47.4952629718296 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the news stories that may have impacted Accern Sentiment’s rankings:

Shares of Acceleron Pharma (NASDAQ XLRN) opened at $36.97 on Friday. Acceleron Pharma has a twelve month low of $23.07 and a twelve month high of $40.35.

Acceleron Pharma (NASDAQ:XLRN) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.02. Acceleron Pharma had a negative return on equity of 40.70% and a negative net margin of 759.34%. The firm had revenue of $3.00 million during the quarter, compared to the consensus estimate of $3.52 million. During the same period in the prior year, the firm earned ($0.55) EPS. The firm’s quarterly revenue was up .0% compared to the same quarter last year. analysts forecast that Acceleron Pharma will post -2.67 EPS for the current fiscal year.

Several research analysts have weighed in on XLRN shares. Credit Suisse Group set a $35.00 price target on Acceleron Pharma and gave the company a “buy” rating in a report on Saturday, August 5th. HC Wainwright boosted their price target on Acceleron Pharma from $57.00 to $62.00 and gave the company a “buy” rating in a report on Tuesday, November 7th. Cann reiterated a “hold” rating on shares of Acceleron Pharma in a report on Tuesday, September 5th. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Acceleron Pharma in a report on Tuesday, September 5th. Finally, BidaskClub downgraded Acceleron Pharma from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $44.88.

COPYRIGHT VIOLATION WARNING: This news story was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.com-unik.info/2017/11/17/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-acceleron-pharma-xlrn-stock-price.html.

In other Acceleron Pharma news, SVP Christopher Rovaldi sold 14,000 shares of the company’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $38.41, for a total value of $537,740.00. Following the completion of the transaction, the senior vice president now directly owns 28,232 shares of the company’s stock, valued at approximately $1,084,391.12. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Kevin F. Mclaughlin sold 16,000 shares of the company’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $38.41, for a total transaction of $614,560.00. Following the completion of the transaction, the chief financial officer now directly owns 50,810 shares of the company’s stock, valued at $1,951,612.10. The disclosure for this sale can be found here. Over the last quarter, insiders sold 53,513 shares of company stock valued at $2,055,485. 3.90% of the stock is owned by insiders.

About Acceleron Pharma

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Insider Buying and Selling by Quarter for Acceleron Pharma (NASDAQ:XLRN)

What are top analysts saying about Acceleron Pharma Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Acceleron Pharma Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit